Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects
Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects
复制标题
DOI：
10.2165/00003088-200847010-00006
复制
发表时间：
2008-01-01
影响因子：
4.5
通讯作者：
Hellriegel, Edward T.
中科院分区：
文献类型：
--
作者：
Darwish, Mona;Kirby, Mary;Hellriegel, Edward T.
背景与目的：阿莫达非尼是一种促醒药物，是外消旋莫达非尼的纯R-对映体。本文的目的是总结三项临床药物相互作用研究的结果，评估阿莫达非尼与细胞色素P450(CYP)酶1A2、3A4和2C19代谢的药物相互作用的可能性。研究1以口服咖啡因为探针底物评价阿莫达非尼诱导细胞色素P1A2活性的潜力。研究2以静脉和口服咪达唑仑为探针底物，评价阿莫达非尼诱导胃肠道和肝脏细胞色素P3A4活性的可能性。研究3以口服奥美拉唑为探针底物，评价阿莫达非尼抑制细胞色素P450酶活性的可能性。
Background and objective: Armodafinil, a wakefulness-promoting agent, is the pure R-enantiomer of racemic modafinil. The objective of this article is to summarize the results of three clinical drug-interaction studies assessing the potential for drug interactions of armodafinil with agents metabolized by cytochrome P450 (CYP) enzymes 1A2, 3A4 and 2C19. Study 1 evaluated the potential for armodafinil to induce the activity of CYP1A2 using oral caffeine as the probe substrate. Study 2 evaluated the potential for armodafinil to induce gastrointestinal and hepatic CYP3A4 activity using intravenous and oral midazolam as the probe substrate. Study 3 evaluated the potential for armodafinil to inhibit the activity of CYP2C19 using oral omeprazole as the probe substrate.Methods: Healthy men and nonpregnant women aged 18-45 years with a body mass index of